Literature DB >> 19652455

Effects of acute intravenous administration of pentamidine, a typical hERG-trafficking inhibitor, on the cardiac repolarization process of halothane-anesthetized dogs.

Hirofumi Yokoyama1, Yuji Nakamura, Hiroshi Iwasaki, Yukitoshi Nagayama, Kiyotaka Hoshiai, Yoshitaka Mitsumori, Atsushi Sugiyama.   

Abstract

Although acute treatment of pentamidine does not directly modify any ionic channel function in the heart at clinically relevant concentrations, its continuous exposure can prolong QT interval. Recent in vitro studies have indicated that hERG trafficking inhibition may play an important role in the onset of pentamidine-induced long QT syndrome. In this study, we examined acute in vivo electropharmacological effects of pentamidine using the halothane-anesthetized canine model (n = 5). The clinically relevant total dose of 4 mg/kg of pentamidine (namely, 1 mg/kg, i.v. over 10 min followed by 3 mg/kg, i.v. over 10 min with a pause of 20 min) decreased the mean blood pressure, ventricular contraction, preload to the left ventricle, and peripheral vascular resistance. Pentamidine also enhanced the atrioventricular conduction in parallel with its cardiohemodynamic actions, but it gradually prolonged both the ventricular repolarization period and effective refractory period, whereas no significant change was detected in the intraventricular conduction. Thus, acute administration of a clinically relevant dose of pentamidine can suppress cardiac function and vascular tone with reflex-mediated increase of sympathetic activity, whereas it may delay the repolarization process, suggesting that inhibition of potassium-channel trafficking might be induced more acutely in vivo than those previously expected in vitro.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19652455     DOI: 10.1254/jphs.09071fp

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  3 in total

1.  The anti-protozoal drug pentamidine blocks KIR2.x-mediated inward rectifier current by entering the cytoplasmic pore region of the channel.

Authors:  T P de Boer; L Nalos; A Stary; B Kok; M J C Houtman; G Antoons; T A B van Veen; J D M Beekman; B L de Groot; T Opthof; M B Rook; M A Vos; M A G van der Heyden
Journal:  Br J Pharmacol       Date:  2010-02-24       Impact factor: 8.739

Review 2.  Cardiac and renal inward rectifier potassium channel pharmacology: emerging tools for integrative physiology and therapeutics.

Authors:  Daniel R Swale; Sujay V Kharade; Jerod S Denton
Journal:  Curr Opin Pharmacol       Date:  2013-11-26       Impact factor: 5.547

3.  The inward rectifier current inhibitor PA-6 terminates atrial fibrillation and does not cause ventricular arrhythmias in goat and dog models.

Authors:  Yuan Ji; Rosanne Varkevisser; Dragan Opacic; Alexandre Bossu; Marion Kuiper; Jet D M Beekman; Sihyung Yang; Azinwi Phina Khan; Dobromir Dobrev; Niels Voigt; Michael Zhuo Wang; Sander Verheule; Marc A Vos; Marcel A G van der Heyden
Journal:  Br J Pharmacol       Date:  2017-06-28       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.